期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

伐地那非的安全性和耐受性 被引量：2

Safety and Tolerability of Vardenafil
下载PDF
导出
摘要 本文回顾了伐地那非治疗勃起功能障碍(erectile dysfunction,ED)的安全性和耐受性,包括其总体安全性、心血管安全性和视觉安全性。临床试验和实际应用的实践经验证明,最常见的不良事件为头痛、颜面潮红和鼻充血,并且多为轻、中度和一过性。无论在一般ED人群中还是在难治性ED人群中,无论是短期还是长期应用,伐地那非均有良好的安全性和耐受性。 This paper reviewed the safety and tolerability of vardenafil in the treatment of erectile dysfunction（ ED）, including the general, cardiovascular and ocular safety. Results from clinical trials and practice experience demonstrated that vadenafil had good safety and tolerability, whether for general ED population or for diffficult-to-treat ED patients, whether as short-term treatment or as long-term therapy.
作者 洪锴 姜辉
机构地区 北京大学第三医院泌尿外科
出处 《中华男科学杂志》 CAS CSCD 2006年第9期857-860,共4页 National Journal of Andrology
关键词 伐地那非 安全性 耐受性 vardenatil safety tolerability
分类号 R983 [医药卫生—药品]
  • 相关文献

参考文献14

  • 1Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial[J]. J Androl, 2002, 23(6) : 763-771.
  • 2Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first athome clinical trail [J]. Int J Impot Res, 2001, 13 (4):192-199.
  • 3Hatzichristou D, Montorsi F, Buvat J, et al. The efficacy and safety of flexible-dose vardenafil ( Levitra? ) in a broad population of European men[J]. Eur Urol, 2004, 45(5) : 634-641.
  • 4金杰,贺占举,张凯,朱积川,姜辉,潘天明,庄申镕,洪铠,唐文豪,马洪铭,王晓雄,何学酉,宋涛,黄翼然,周立新,戴继灿,丁强,方杰,徐罡,蔡松良,陈军,金晓东,郭应禄.伐地那非治疗勃起功能障碍的多中心、随机、双盲、对照研究[J].中华泌尿外科杂志,2005,26(1):54-58. 被引量：5
  • 5Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a muhicenter double-blind placebo-controlled fixed-dose study [J]. Diabetes Care, 2003, 26(3):777-783.
  • 6Rosen R, Montorsi F, Assalian P, et al. Efficacy and tolerability of vardenafil in men with mild depressive disorder and erection dysfunction : The Depression Related Improvement with Vardenafil for Erectile Response (DRIVER) Study [M]. Presented at the 19th Congress of the European Association of Urology, 26 March 2004, Vienna, Austria.
  • 7Brock G, Nehra A, Lipshuhz LI, et al. Safety and efficacy of vardenatil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy [J]. J Urol, 2003, 170 (4 Pt 1):1278-1283.
  • 8Stief C, Porst H, Saenz de Tejada I, et al. Sustained efficacy and tolerability with vardenatil over 2 years of treatment in mens with erectile dysfunction[J]. Int J Clin Pract, 2004, 58(3) : 230-239.
  • 9H van Ahlen, Zumb6 J, Stanch K, et al. The real-life safety and efficacy of vardenafil: an international post-marketting surveillance study-results from 29 358 German patients[J]. The Journal of International Medical Research, 2005, 33 (3) : 337-348.
  • 10Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction [J].Circulation, 2004, 110(19) : 3149-3155.

二级参考文献16

  • 1Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences[J]. BJU Int, 1999, 84(1): 50-56.
  • 2Nehra A, Kulaksizoglu H. Global perspectives and controversies in the epidemiology of male erectile dysfunction [J]. Cuur Opin Urol, 2002, 12(6): 493-496.
  • 3Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial [J]. J Androl, 2002, 23(6) :763-771.
  • 4Donatucci C, Pommerville P, Niederberger C, et al. Vardenafil improved patient satisfaction with erection hardness, orgasmic function, and sexual experience in men with erectile dysfunction [J]. J Urol, 2003, 169(Supp14): 246.
  • 5Valiquette L, Hellstrom W, Gittelman M. Vardenafil provides reliable efficacy over time in men with erectile dysfunction [J]. Int J Impot Res, 2002, 14(Suppl 3): S88.
  • 6Stief C, Porst H, Saenz de Tejada Ⅰ, et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erecitle dysfunction[J]. Int J Clin Pract, 2004, 58 (3): 230- 239.
  • 7Padm a-Nathan H, Eardley Ⅰ, Collins O, et al. Vardenafil restores normal functioning to men with erectile dysfunction [J]. J Urol,2002, 167(4 Suppl): 177.
  • 8Goldstein Ⅰ, Young JM, Fishcher J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind pla cebo-controlled fixed-dose study [J]. Diabetes Care, 2003, 26 (3): 777-783.
  • 9Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first athome clinical trail[J]. Int J Impot Res, 2001 , 13 (4): 192-199.
  • 10Kloner RA, Mohan P, Norenberg C, et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE-5 inhibitor in patients with erectile dysfunction: an analysis of five placebo-controlled clinical trials [J]. Pharmacotherapy, 2002, 22 (10):1371.

共引文献13

同被引文献13

  • 1金杰,郭应禄.伐地那非的药效学和药代动力学[J].中华男科学杂志,2004,10(9):711-716. 被引量：5
  • 2王晓雄.伐地那非治疗糖尿病患者的勃起功能障碍[J].中华男科学杂志,2004,10(10):794-797. 被引量：3
  • 3金杰,贺占举,张凯,朱积川,姜辉,潘天明,庄申镕,洪铠,唐文豪,马洪铭,王晓雄,何学酉,宋涛,黄翼然,周立新,戴继灿,丁强,方杰,徐罡,蔡松良,陈军,金晓东,郭应禄.伐地那非治疗勃起功能障碍的多中心、随机、双盲、对照研究[J].中华泌尿外科杂志,2005,26(1):54-58. 被引量：5
  • 4王传航.伐地那非在难治性ED人群中的应用[J].中华男科学杂志,2006,12(4):377-380. 被引量：3
  • 5Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type5 inhibitor, in the treatment of erectiledysfunction in men with diabetes:multicenter double-blind placebocontrolled fixed does study[ J ]. Diabetes Care, 2003, 26 (3) : 777-783.
  • 6Dey J, Shepherd MD. Evaluation and treatment of exectile dysfunction in men with diabetes mellitus [ J ]. Mayo Clin Proc, 2002, 77 (3) :276-282.
  • 7De Berardis G, Franciosi M, Belfiglio M, et al. Erectile dysfunctiln and quality of life in type 2 diabetic patients: a serious problem too often overlooked[J]. Diabetes Care, 2002,25(2) : 284-291.
  • 8Dunsmuir WD, Holmes SA. The aetiology and maragement of erectile, ejaculatory and fertility problem in men with diabetes mellitus[J]. Diabete Med, 1996, 13(8):700-708.
  • 9Yildirim S, Ayan S, Sarioglu Y, et al. The effects of long-term oral administration of L-arginine on the erectile response of rabbits with alloxan-induced diabetes[J]. BJU Int, 1999, 83(6) : 679-685.
  • 10Khan MA, Thompson CS, Jeremy JY, et al. The effect of superoxide dismutase on nitric oxide-mediated and electrical fieldstimulated diabetic rabbit cavernosal smooth muscle relaxation [J]. BJU Int, 2001,87(1) :98-103.

引证文献2

二级引证文献6

中华男科学杂志
2006年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部